



Aflibercept: Eylea[®]; Eylea[®] HD (Intravitreal)

Document Number: MH-0026

Last Review Date: 09/05/2023 Date of Origin: 02/07/2013 Dates Reviewed: 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015, 06/2015, 09/2015, 03/2016, 04/2016, 05/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018, 10/2018, 06/2019, 10/2019, 10/2020, 02/2021, 10/2021, 10/2022, 03/2023, 05/2023, 09/2023

I. Length of Authorization ¹

Coverage will be provided annually and may be renewed, unless otherwise specified.

• Coverage for Retinopathy of Prematurity (ROP) will be provided initially for a total of 2 doses (1 dose per eye) and may be renewed as re-treatment for up to an additional 4 doses (2 doses per eye) (*Refer to Section IV for re-treatment criteria*)

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

<u>Eylea:</u>

• 2 mg/0.05 mL injection: 1 vial/pre-filled syringe per eye every 28 days

<u>Eylea HD:</u>

• 8 mg/0.07 mL injection: 1 vial/kit per eye every 28 days

B. Max Units (per dose and over time) [HCPCS Unit]:

	Eylea		Eylea HD	
Diagnosis	Initial Dosing	Maintenance Dosing	Initial Dosing	Maintenance Dosing
Neovascular age-related	4 units every 28	4 units every 28-	16 units (16 mg) every	16 units (16 mg)
macular degeneration (AMD)	days x 3 doses	56 days	28 days x 3 doses	every 56 to 112 days
Macular edema following retinal	4 units every 28	4 units every 28	N/A	N/A
vein occlusion (RVO)	days	days		
Diabetic Macular Edema (DME)/	4 units every 28	4 units every 28-	16 units (16 mg) every	16 units (16 mg)
Diabetic Retinopathy (DR)	days x 5 doses	56 days	28 days x 3 doses	every 56 to 112 days
Retinopathy of Prematurity (ROP)	0.8 units x 1 dose	0.8 units every 10	N/A	N/A
		days x 2 doses		



(Max units are based on administration to both eyes)

III. Initial Approval Criteria ¹⁻¹⁵

Coverage is provided in the following conditions:

- Patient must try and have an inadequate response (defined as 3 months or 3 injections into a single eye with minimal to no improvement), clinically significant adverse effects, or contraindication to Avastin (bevacizumab) prior to consideration of a non-preferred product. Documentation of contraindication, adverse events, or date(s) of failed therapy to Avastin (bevacizumab) required; **AND**
- Patient is at least 18 years of age, unless otherwise specified; AND

Universal Criteria¹

- Patient is free of ocular and/or peri-ocular infections; AND
- Patient does not have active intraocular inflammation; AND
- Therapy will not be used with other ophthalmic VEGF inhibitors (i.e., brolucizumab-dbll, ranibizumab, pegaptanib, bevacizumab, faricimab-svoa, etc.); **AND**
- Patient's best corrected visual acuity (BCVA) is measured at baseline and periodically during treatment (*Note: NOT applicable to patients with Retinopathy of Prematurity*), AND
- Patient has a definitive diagnosis of one of the following:

Neovascular (Wet) Age-Related Macular Degeneration (nAMD) **

Macular Edema following Retinal Vein Occlusion (RVO) † (Eylea Only)

Diabetic Macular Edema (DME) **†***

Diabetic Retinopathy (DR) **

Retinopathy of Prematurity (ROP) $\dagger \Phi$ (Eylea Only)

• Patient is a premature infant with a maximum gestational age at birth of 32 weeks OR a birth weight of >800 to 1500 g

*Eylea Only: Patients with an insufficient response during initial therapy administered every 4 weeks may continue with dosing every 4 weeks. Patients with an inadequate response to maintenance therapy administered every 8 weeks may increase the dosing frequency up to every 4 weeks. (Refer to Section V)

FDA Approved Indication(s); Compendia recommended indication(s); Orphan Drug

IV. Renewal Criteria ¹⁻¹⁵

Coverage can be renewed based upon the following criteria:

• Patient continues to meet the universal and indication-specific relevant criteria as identified in section III; **AND**



• Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: endophthalmitis and retinal detachments, increase in intraocular pressure, arterial thromboembolic events; **AND**

Retinopathy of Prematurity (ROP) (Eylea Only)

- Patient still has the presence of active ROP requiring treatment; AND
- At least 10 days have elapsed since receiving initial treatment

All Other Indications

• Patient has had a beneficial response to therapy (e.g., improvement in the baseline best corrected visual acuity (BCVA), etc.) and continued administration is necessary for the maintenance treatment of the condition

V. Dosage/Administration ^{1,2}

Page 3

Indication	Dose
Neovascular (Wet) AMD	 Eylea Only Initiation: Administer 2 mg intravitreally per affected eye once every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months) Maintenance: Administer 2 mg intravitreally per affected eye once every 8 weeks (2 months); however, Eylea may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly) • Additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (approximately monthly) dosing after the first 12 weeks (3 months). Patients may also be treated with one dose every 12 weeks after one year of effective therapy Eylea HD Only The recommended dose is 8 mg administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.
Macular Edema following RVO	Eylea Only Administer 2 mg intravitreally per affected eye once every 4 weeks (approximately every 25 days, monthly)
Diabetic Macular Edema (DME) & Diabetic Retinopathy (DR)	Eylea Only Initiation: Administer 2 mg intravitreally per affected eye once every 4 weeks (approximately every 28 days, monthly) for the first 5 injections <u>Maintenance</u> :



	 Administer 2 mg intravitreally per affected eye once every 8 weeks (2 months); however, Eylea may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly) Additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).
	Eylea HD Only
	The recommended dose is 8 mg administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.
	Eylea Only
	Administer 0.4 mg intravitreally per affected eye.
Retinopathy of	• Injections may be given bilaterally on the same day.
Prematurity (ROP)	• Injections may be repeated in each eye and the treatment interval between doses injected into the same eye should be at least 10 days.
	• <u>NOTE</u> : Treatment for this indication is ONLY applicable to the single-dose vial kit. Do NOT use the pre-filled syringe for the treatment of ROP.

VI. Billing Code/Availability Information

HCPCS Code(s):

- J0178 Injection, aflibercept, 1 mg; 1 billable unit = 1 mg (*Eylea Only*)
- J0177 Injection, aflibercept hd, 1 mg; 1 billable unit = 1 mg (*Eylea HD Only*) (*Effective* 04/01/2024)
- J3590 Unclassified biologics (Eylea HD Only) (Discontinue use on 04/01/2024)
- C9161 Injection, aflibercept hd, 1 mg; 1 billable unit = 1 mg (*Eylea HD Only*) (*Discontinue use on 04/01/2024*)

NDC(s):

- Eylea 2 mg/0.05 mL Solution for Injection, single-dose vial kit or single-dose pre-filled syringe: 61755-0005-xx
- Eylea 8 mg/0.07 mL Solution for Injection, single-dose vial kit: 61755-0050-xx
- Eylea 8 mg/0.07 mL Solution for Injection, single-dose vial: 61755-0051-xx

VII. References

- 1. Eylea [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; February 2023. Accessed April 2023.
- 2. Eylea HD [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; August 2023. Accessed August 2023.
- 3. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW.



Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Mar 26; 372(13): 1193–1203. DOI: 10.1056/NEJMoa1414264

- 4. John A. Wells JA, Adam R. Glassman, Lee M. Jampol, Lloyd Paul Aiello, Andrew N. Antoszyk, Carl W. Baker, Neil M. Bressler, David J. Browning, Crystal G. Connor, Michael J. Elman, Frederick L. Ferris, Scott M. Friedman, Michele Melia, Dante J. Pieramici, Jennifer K. Sun, Roy W. Beck, for the Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness with 1-year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599
- 5. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet agerelated macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48.
- 6. Szabo SM, Hedegaard M, Chan K, et al. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. Curr Med Res Opin. 2015 Nov;31(11):2031-42.
- Gillies MC, Nguyen V, Daien V, et al. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2016 Dec;123(12):2545-2553.
- Barthelmes D, Campain A, Nguyen P, et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016 Dec;100(12):1640-1645.
- 9. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Mar;40(3):412-418.
- American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Committee, Hoskins Center for Quality Eye Care. Diabetic Retinopathy PPP – Update 2019. Oct 2019.
- American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Committee, Hoskins Center for Quality Eye Care. Retinal Vein Occlusions PPP – Update 2019. Oct 2019.
- 12. American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Committee, Hoskins Center for Quality Eye Care. Age-Related Macular Degeneration PPP – Update 2019. Oct 2019.
- 13. Royal College of Ophthalmologists. Clinical Guidelines Retinal Vein Occlusion (RVO) Guidelines – July 2015. Accessed at https://www.rcophth.ac.uk/standards-publicationsresearch/clinical-guidelines.
- 14. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 2016;123(6):1351-9. doi.org/10.1016/j.ophtha.2016.02.022.
- 15. Stahl A, Sukgen EA, Wu WC, et al.; FIREFLEYE Study Group. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA. 2022 Jul 26;328(4):348-359. doi: 10.1001/jama.2022.10564.



- 16. National Government Services, Inc. Local Coverage Article: Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Brolucizumab-dbll and Faricimab-svoa (A52451). Centers for Medicare & Medicaid Services, Inc. Updated on 03/24/2023 with effective date of 04/01/2023. Accessed August 2023.
- Palmetto GBA. Local Coverage Article (LCA): Billing and Coding: Aflibercept (EYLEA®) (A53387). Centers for Medicare & Medicaid Services, Inc. Updated on 04/12/2021 with effective date of 04/22/2021. Accessed August 2023.

ICD-10	ICD-10 Description
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with
	macular edema
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without
	macular edema
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	with macular edema, bilateral
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	with macular edema, unspecified eye
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	without macular edema, right eye
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	without macular edema, left eye
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	without macular edema, bilateral
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy
	without macular edema, unspecified eye
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy with macular edema, bilateral
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy with macular edema, unspecified eye
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy without macular edema, right eye
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy without macular edema, left eye
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
	retinopathy without macular edema, bilateral
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic
Rec artic	retinopathy without macular edema, unspecified eye
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	with macular edema, left eye

Appendix 1 – Covered Diagnosis Codes

Page 6 AFLIBERCEPT (Eylea®; Eylea® HD) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2023, Magellan Rx Management



ICD-10	ICD-10 Description
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	with macular edema, bilateral
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	with macular edema, unspecified eye
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	without macular edema, right eye
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	without macular edema, left eye
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	without macular edema, bilateral
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy
	without macular edema, unspecified eye
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with
	macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with
	macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with
	macular edema, bilateral
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with
Rec area	macular edema, unspecified eye
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without
B aa a x aa	macular edema, right eye
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without
	macular edema, left eye
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without
E08.3599	macular edema, bilateral Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without
E00.5599	macular edema, unspecified eye
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following
E00.57A1	treatment, right eye
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following
100.0111	treatment, left eye
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following
	treatment, bilateral
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following
	treatment, unspecified eye
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular
	edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without
	macular edema
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	with macular edema, bilateral
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	with macular edema, unspecified eye
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
Dec coor	without macular edema, right eye
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	without macular edema, left eye



ICD-10	ICD-10 Description
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	without macular edema, bilateral
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy
	without macular edema, unspecified eye
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
	retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
-	retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
	retinopathy with macular edema, bilateral
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
	retinopathy with macular edema, unspecified eye
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
R 00.0000	retinopathy without macular edema, right eye
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
E00 0000	retinopathy without macular edema, left eye
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
E09.3399	retinopathy without macular edema, bilateral Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic
E09.3399	
E09.3411	retinopathy without macular edema, unspecified eye Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
E09.3411	with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
E05.5412	with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
100.0410	with macular edema, bilateral
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
	with macular edema, unspecified eye
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
	without macular edema, right eye
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
	without macular edema, left eye
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
	without macular edema, bilateral
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy
	without macular edema, unspecified eye
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with
	macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with
	macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with
E00.0510	macular edema, bilateral
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with
F00.2501	macular edema, unspecified eye
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without
E09.3592	macular edema, right eye Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without
109.0092	macular edema, left eye
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without
L00.0000	macular edema, bilateral
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without
	macular edema, unspecified eye

Page 8



ICD-10	ICD-10 Description
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

AFLIBERCEPT (Eylea®; Eylea® HD) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2023, Magellan Rx Management

Page 9



ICD-10	ICD-10 Description
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

Page 10 I AFLIBERCEPT (Eylea®; Eylea® HD) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2023, Magellan Rx Management



ICD-10	ICD-10 Description
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular
	edema, right eye
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular
D 44 0000	edema, left eye
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular
E11.3399	edema, bilateral Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular
Е11.5599	edema, unspecified eye
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular
	edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular
	edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular
D	edema, bilateral
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular
E11.3491	edema, unspecified eye Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular
E11.0491	edema, right eye
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular
	edema, left eye
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular
	edema, bilateral
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular
D11 0F11	edema, unspecified eye
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right
	eye
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left
E11 9509	eye
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,
	unspecified eye
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,
	unspecified eye
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular
E13.3212	edema, right eye Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular
110.0414	edema, left eye
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular
	edema, bilateral

Page 11 I AFLIBERCEPT (Eylea®; Eylea® HD) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2023, Magellan Rx Management



ICD-10	ICD-10 Description
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular
	edema, unspecified eye
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without
	macular edema, right eye
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without
	macular edema, left eye
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without
110.0200	macular edema, bilateral
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without
110.0200	macular edema, unspecified eye
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with
E10.0011	macular edema, right eye
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with
E15.5512	macular edema, left eye
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with
E19.9919	macular edema, bilateral
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with
Е19.9919	macular edema, unspecified eye
E10 0001	
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without
E10.0000	macular edema, right eye
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without
B 10.0000	macular edema, left eye
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without
B 40.0000	macular edema, bilateral
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without
F 10.0411	macular edema, unspecified eye
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with
	macular edema, right eye
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with
	macular edema, left eye
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with
	macular edema, bilateral
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with
	macular edema, unspecified eye
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without
	macular edema, right eye
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without
	macular edema, left eye
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without
	macular edema, bilateral
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without
	macular edema, unspecified eye
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema,
	right eye
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema,
	left eye
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema,
	bilateral
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema,
	unspecified eye
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular



ICD-10	ICD-10 Description
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular
Dia akao	edema, left eye
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular
	edema, unspecified eye
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment,
E13.37X2	right eye Other specified diabetes mellitus with diabetic macular edema, resolved following treatment,
110.0111	left eye
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8190	Central retinal vein occlusion, unspecified eye, with macular edema
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8390	Tributary (branch) retinal vein occlusion, unspecified eye, with macular edema
H35.1	Retinopathy of prematurity
H35.10	Retinopathy of prematurity, unspecified
H35.101	Retinopathy of prematurity, unspecified, right eye
H35.102	Retinopathy of prematurity, unspecified, left eye
H35.103	Retinopathy of prematurity, unspecified, bilateral
H35.109	Retinopathy of prematurity, unspecified, unspecified eye
H35.111	Retinopathy of prematurity, stage 0, right eye
H35.112	Retinopathy of prematurity, stage 0, left eye
H35.113	Retinopathy of prematurity, stage 0, bilateral
H35.119	Retinopathy of prematurity, stage 0, unspecified eye
H35.121	Retinopathy of prematurity, stage 1, right eye
H35.122	Retinopathy of prematurity, stage 1, left eye
H35.123	Retinopathy of prematurity, stage 1, bilateral
H35.129	Retinopathy of prematurity, stage 1, unspecified eye
H35.131	Retinopathy of prematurity, stage 2, right eye
H35.132	Retinopathy of prematurity, stage 2, left eye
H35.133	Retinopathy of prematurity, stage 2, bilateral
H35.139	Retinopathy of prematurity, stage 2, unspecified eye
H35.141	Retinopathy of prematurity, stage 3, right eye
H35.142	Retinopathy of prematurity, stage 3, left eye
H35.142	Retinopathy of prematurity, stage 3, bilateral
H35.149	Retinopathy of prematurity, stage 3, unspecified eye
1150.149	neunopamy or prematurity, stage 5, unspecified eye

AFLIBERCEPT (Eylea®; Eylea® HD) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2023, Magellan Rx Management

ICD-10	ICD-10 Description
H35.151	Retinopathy of prematurity, stage 4, right eye
H35.152	Retinopathy of prematurity, stage 4, left eye
H35.153	Retinopathy of prematurity, stage 4, bilateral
H35.159	Retinopathy of prematurity, stage 4, unspecified eye
H35.161	Retinopathy of prematurity, stage 5, right eye
H35.162	Retinopathy of prematurity, stage 5, left eye
H35.163	Retinopathy of prematurity, stage 5, bilateral
H35.169	Retinopathy of prematurity, stage 5, unspecified eye
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.3290	Exudative age-related macular degeneration, unspecified eye, stage unspecified
H35.3291	Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization
H35.3292	Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization
H35.3293	Exudative age-related macular degeneration, unspecified eye, with inactive scar

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA):

Jurisdiction(s): 6, K NCD/LCD/LCA Document (s): A52451	
--	--



https://www.cms.gov/medicare-coverage-database/new-search/searchresults.aspx?keyword=a52451&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CM CD%2C6%2C3%2C5%2C1%2CF%2CP

Jurisdiction(s): J, M

NCD/LCD/LCA Document (s): A53387

<u>https://www.cms.gov/medicare-coverage-database/new-search/search-</u> results.aspx?keyword=a53387&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CM CD%2C6%2C3%2C5%2C1%2CF%2CP

Medicare Part B Administrative Contractor (MAC) Jurisdictions			
Jurisdiction	Applicable State/US Territory	Contractor	
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC	
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC	
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)	
6	MN, WI, IL	National Government Services, Inc. (NGS)	
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.	
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)	
N (9)	FL, PR, VI	First Coast Service Options, Inc.	
J (10)	TN, GA, AL	Palmetto GBA, LLC	
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC	
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.	
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)	
15	КҮ, ОН	CGS Administrators, LLC	

